Abbott Follows Pfizer To FDA With Co-Developed Lung Cancer Diagnostic
This article was originally published in The Gray Sheet
Executive Summary
A 2009 collaboration agreement with Pfizer could start bearing fruit for Abbott Molecular by year end, with the firms' lung cancer drug-diagnostic combination now under review at FDA.
You may also be interested in...
Team Work: Pfizer, Abbott Gain Swift Approvals For Lung Cancer Drug/Test Combo
Following simultaneous and swift FDA approvals, Abbott Molecular Diagnostics is launching its Vysis ALK molecular test to identify the small percentage of non-small-cell lung cancer patients who would respond to Pfizer’s Xalkori (crizotinib) cancer drug.
Team Work: Pfizer, Abbott Gain Swift Approvals For Lung Cancer Drug/Test Combo
Following simultaneous and swift FDA approvals, Abbott Molecular Diagnostics is launching its Vysis ALK molecular test to identify the small percentage of non-small-cell lung cancer patients who would respond to Pfizer’s Xalkori (crizotinib) cancer drug.
FDA Companion Dx Draft Guidance: Broad In Scope, Limited In Detail
FDA's draft guidance on the development of companion diagnostics for drug therapies, released July 12, delivers on a promise to publicly outline how it will address review of those products, but at only 12 pages, it has left some in industry longing for more insight.